By handling many of the technical aspects of bladder cancer detection, GenASIs FISH is a computer aided pathology solution that saves time and increases efficiency while maintaining superior clinical accuracy.
GenASIs FISH - UroVysion
Detection of Chromosomal Aberrations in Bladder Cancer
UroVysion™ is an FDA approved fluorescent in situ hybridization (FISH) assay for diagnosis and monitoring of bladder cancer. Performed on bladder cells excreted in urine, UroVysion checks for aneuploidy in chromosomes 3, 7 and 17, as well as deletion of 9p21.
UroVysion™ requires that 25 morphologically abnormal cells be counted, with “abnormality” being a cell that exhibits either a large nuclei, irregular nuclear border, non-continuous DAPI staining, or cells in clusters.
GenASIs provides reproducible and quantified UroVysion results using multiple workflow methods.
- Manual Capture
- Automatic Capture
GenASIs FISH uses advanced scanning algorithms to efficiently detect, analyze and classify the required number of cells in even sparse samples.
FDA Cleared for Clinical Use